All In Biotech

Drug Trial Radar · NCT01124149

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Jun 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

759

Actual

Start

Jun 29, 2010

Primary completion

Dec 7, 2012

Study completion Dec 7, 2012

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
May 14, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term outcomes and remain in remission longer compared with subjects who demonstrate only partial remission after acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD. Therefore, subjects who achieve either complete or partial remission will enter into a 12-month maintenance phase, during which they will receive MMX mesalamine/mesalazine 2.4g/day given QD. Remission status for the 2 groups will be evaluated and compared at the end of this 12-month maintenance period. The data obtained from this study will provide scientifically meaningful information to demonstrate that achieving complete remission (clinical and endoscopic remission) is important for a better long-term prognosis, or that the current paradigm of symptomatic treatment is appropriate.

Conditions

  • Ulcerative Colitis

Interventions

  • MMX mesalamine/ mesalazineDrug

    4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects in Complete Remission at Month 12 of Maintenance PhaseTime frame: 12 months

Locations

105 sites in 15 countries. Site status is shown where the registry gives one.

  • Birmingham Gastroenterology Associates, PC

    Birmingham, Alabama

  • Advanced Clinical Research Institute

    Anaheim, California

  • Digestive & Liver Disease Specialists

    Garden Grove, California

  • Long Beach VA Medical Center

    Long Beach, California

  • Clinical Applications Laboratories, Inc.

    San Diego, California

  • Conneticut Gastroenterolgy Institute

    Bristol, Connecticut

  • Borland-Groover Clinic

    Jacksonville, Florida

  • United Medical Research

    New Smyrna Beach, Florida

  • Advances Gastroenterology Associates

    Palm Harbor, Florida

  • Atlanta Gastroenterology Associates, LLC

    Atlanta, Georgia

  • Atlanta Gastroenterology Associates

    Marietta, Georgia

  • University of Chicago Medical Center

    Chicago, Illinois

  • Midwest Clinical Research Associates

    Moline, Illinois

  • Gastrointestinal Clinic of Quad Cities

    Davenport, Iowa

  • New Orleans Research Institute

    Metairie, Louisiana

  • Delta Research Partners

    Monroe, Louisiana

  • Louisiana Research Center, LLC

    Shreveport, Louisiana

  • Digestive Disorders Associates

    Annapolis, Maryland

  • Digestive Disease Associates

    Baltimore, Maryland

  • Center for Digestive Health

    Troy, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Center for Digestive & Liver Disease, Inc.

    Mexico, Missouri

  • Long Island Clinical Research Associates, LLP

    Great Neck, New York

  • Gastrointestinal Research Associates

    Setauket, New York

  • LeBauer Research Associates

    Greensboro, North Carolina

  • Ohio Gastroenterolgy and Liver Intstitute

    Cincinnati, Ohio

  • Regional Gastroenterology Associates of Lancaster, Ltd.

    Lancaster, Pennsylvania

  • Gastroenterology Associates, LLC

    Kingsport, Tennessee

  • S.D. Khan

    Houston, Texas

  • Gastroenterology Clinic of San Antonio, PA

    San Antonio, Texas

  • Colon and Rectal Disease Center

    Sandy City, Utah

  • Physicians Research Option, LLC

    Sandy City, Utah

  • Alexandria Clinical Research

    Alexandria, Virginia

  • Wisconsin Center for Advances Research

    Milwaukee, Wisconsin

  • Imelda General Hospital

    Bonheiden, Belgium

  • vzw AZ Groeninge

    Kortrijk, Belgium

  • Heilig Hart ziekenhuis vzw Roeselare-Menen

    Roeselare, Belgium

  • McMaster University Medical Centre

    Hamilton, Ontario, Canada

  • Toronto Digestive Disease Associates, Inc.

    Toronto, Ontario, Canada

  • Royal Victoria Hospital

    Montreal, Quebec, Canada

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.